Table 1 Specific data depending on the pathology and administration of plerixafor.
Pathology | N patients (%) | >1 apheresis procedure (%) | Reduction in second apheresis procedures (%) | Mean blood volumes (range) | Procedures >3 blood volumes (%) | Adverse effects (%) | CE2 (Mean-1SD) |
|---|---|---|---|---|---|---|---|
NHL | 47/129 (36.43) | 11/47 (23.40) | 8/47 (17.03) | 3,38 (1.67-4.40) | 31/47 (65.96) | 2/47 (4.26) | 0,31 (0.46-0.15) |
NHL without plerixafor | 32/129 (24.81) | 4/32 (12.50) | 6/32 (18.75) | 3,24 (1.67-4.40) | 17/32 (53.13) | 2/32 (6.25) | 0,31 (0.43-0.12) |
NHL with plerixafor | 15/129 (11.62) | 7/15 (46.67) | 2/15 (13.33) | 3,67 (2.8-4.23) | 12/15 (80.00) | 0/15 (0.00) | 0,30 (0.48-0.18) |
MM without plerixafor | 52/129 (40.31) | 10/52 (19.23) | 8/52 (15.38) | 3,32 (1.87-4.14) | 35/52 (67.31) | 4/52 (7.69) | 0,35 (0.47-0.12) |
MM with plerixafor | 30/129 (23.26) | 3/30 (10.00) | 3/30 (10.00) | 3,34 (2.47-4.19) | 17/30 (56.67) | 2/30 (6.67) | 0,32 (0.45-0.13) |
